Unresectable or metastatic SSTR2 expressing neuroendocrine tumors (NETs)
CATXPerspective TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for [212Pb]VMT-α-NET in Unresectable or metastatic SSTR2 expressing neuroendocrine tumors (NETs). The expected timing is based on the latest available company guidance and may change.
07/31/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.